<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309669</url>
  </required_header>
  <id_info>
    <org_study_id>TOT401-19</org_study_id>
    <nct_id>NCT04309669</nct_id>
  </id_info>
  <brief_title>Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia</brief_title>
  <acronym>FAST</acronym>
  <official_title>Assessment of the eFficacy, the Onset-of-Action and the Safety of Tot'héma® in Adults With Moderate Iron Deficiency Anaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoire Innotech International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoire Innotech International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess, in patients with moderate IDA, the Onset-of-Action of a
      daily treatment with Tot'Héma®. The onset of action is defined as the time required for a
      mean increase of at least 0,5g/dL from baseline in the haemoglobin level.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess, in patients with moderate IDA, the Onset-of-Action of a daily treatment with Tot'Héma®. The onset of action is defined as the time required for a mean increase of at least 0,5g/dL from baseline in the haemoglobin level.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Identification of the first time (in days) associated with a mean increase in the haemoglobin level of at least 0.5 g/dL (versus mean haemoglobin level at D0).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Tot'hema</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three ampoules per day during 12 weeks daily dose: 150mg of iron per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOT'HEMA</intervention_name>
    <description>three ampoules per day during 12 weeks</description>
    <arm_group_label>Tot'hema</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult men and women (&gt;18 years)

          2. Patient with a confirmation of moderate anemia defined as: 8 g/dL ≤ Haemoglobin level
             ≤ 9 g/dL on the last hematological test performed within 7 days before inclusion
             visit.

          3. Patient with ferritin blood level &lt; lower limit of laboratory standard for this
             biological parameter at on the last hematological test performed within 7 days before
             inclusion visit.

          4. Patient who has read, understood, dated and signed the informed consent form

        6. Patient agreeing to comply with protocol requirements, including visits and blood
        samples at specifically defined dates

        Non-inclusion Criteria:

          1. Patient for whose an oral iron supplementation is not indicated or not recommended
             according to PI's opinion

          2. CRP &gt; 10 mg/L on the last hematological test performed within 7 days before inclusion
             visit.

          3. Patient with benign or malignant neoplastic tumour

          4. Patient presenting gastrointestinal disorders incompatible with study treatment
             compliance

          5. Pregnant or breastfeeding woman

          6. Woman with childbearing potential who does not agree to use an accepted highly
             effective method of contraception - per investigator's judgment

          7. Patient with surgery scheduled to occur during the treatment period

          8. Patient allergic or hypersensitive to any of the components of Tot'Héma® ampoule

          9. Patient with chronic inflammatory disease, including chronic inflammatory bowel
             syndrome and/or chronic heart failure and/or chronic renal failure and/or inflammatory
             rheumatism

         10. Patient with active digestive bleeding (such as digestive ulcer)

         11. Patient having taken iron supplementation, iron-based IV therapy or mineral
             supplementation with iron, within the 15 days prior to the inclusion visit (V2)

         12. Patient with fructose intolerance, glucose-galactose malabsorption syndrome or
             sucrase-isomaltase deficiency

         13. Patient with acute malaria crisis within 15 days prior to inclusion

         14. Patient with a positive Faecal Occult Blood Test (FOBT)

         15. Patient with HIV infection

         16. Unreliable patients, including non-observant patients, patients with known alcoholism
             or drug abuse, or with a history of a serious psychiatric disorder, as well as
             patients who are reluctant to give informed consent or to comply with protocol
             requirement.

        Selection criterion 1. Patient with moderate anaemia defined as 8 g/dL ≤ haemoglobin level
        ≤ 9 g/dL on the last hematological test performed within 7 days before screening visit

        Inclusion criteria

        1. Adult men and women (≥18 years) 2. Patient with a confirmation of moderate anaemia
        defined as 8 g/dL ≤ haemoglobin level ≤ 9 g/dL on the last hematological test performed
        within 7 days before inclusion visit 3. Patient with ferritin blood level &lt; lower limit of
        laboratory standard for this biological parameter on the last hematological test performed
        within 7 days before inclusion visit 4. Patient who has read, understood, dated and signed
        the informed consent form 5. Patient agreeing to comply with protocol requirements,
        including visits and blood samples at specifically defined dates Non-inclusion criteria

          1. Patient for whom an oral iron supplementation is not indicated or not recommended
             according to Investigator's opinion

          2. C-Reactive Protein &gt; 10 mg/L on the last hematological test performed within 7 days
             before inclusion visit

          3. Patient with benign or malignant neoplastic tumour

          4. Patient presenting gastrointestinal disorders incompatible with study treatment
             compliance

          5. Pregnant or breastfeeding woman

          6. Woman with childbearing potential who does not agree to use an accepted highly
             effective method of contraception - per investigator's judgment

          7. Patient with surgery scheduled to occur during the treatment period

          8. Patient allergic or hypersensitive to any of the components of Tot'héma® ampoule

          9. Patient with chronic inflammatory disease, including chronic inflammatory bowel
             syndrome and/or chronic heart failure and/or chronic renal failure and/or inflammatory
             rheumatism

         10. Patient with active digestive bleeding (such as digestive ulcer)

         11. Patient having taken iron supplementation, iron-based IV therapy mineral
             supplementation with iron within the 15 days prior to the inclusion visit (V2)

         12. Patient with fructose intolerance, glucose-galactose malabsorption syndrome or
             sucrase-isomaltase deficiency

         13. Patient with acute malaria crisis within 15 days prior to inclusion

         14. Patient with a positive Faecal Occult Blood Test (FOBT)

         15. Patient with HIV infection

         16. Unreliable patients, including non-observant patients, patients with known alcoholism
             or drug abuse, or with a history of a serious psychiatric disorder, as well as
             patients who are reluctant to give informed consent or to comply with protocol
             requirement.

         17. Patient with a family relationship to a person at the investigator's site or at the
             Sponsor or at the CRO.

         18. Participant involved in another interventional or observational clinical trial or who
             participated in another interventional clinical trial within four weeks before
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

